Cargando…
Autoantibody Against Ferritin Light Chain is a Serum Biomarker for the Detection of Liver Cirrhosis but Not Liver Cancer
PURPOSE: Ferritin is a protein that plays an important role in iron metabolism, it consists of two subunits: heavy chain (FTH) and light chain (FTL). Elevated expression of FTL is observed in multiple malignancies. Recent studies have found that the frequency of circulating autoantibody against FTL...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8976487/ https://www.ncbi.nlm.nih.gov/pubmed/35378780 http://dx.doi.org/10.2147/JHC.S352057 |
_version_ | 1784680580438294528 |
---|---|
author | Ren, Pengfei Wang, Keyan Ma, Jie Cao, Xiaoqin Zhao, Jiuzhou Zhao, Chengzhi Guo, Yongjun Ye, Hua |
author_facet | Ren, Pengfei Wang, Keyan Ma, Jie Cao, Xiaoqin Zhao, Jiuzhou Zhao, Chengzhi Guo, Yongjun Ye, Hua |
author_sort | Ren, Pengfei |
collection | PubMed |
description | PURPOSE: Ferritin is a protein that plays an important role in iron metabolism, it consists of two subunits: heavy chain (FTH) and light chain (FTL). Elevated expression of FTL is observed in multiple malignancies. Recent studies have found that the frequency of circulating autoantibody against FTL (anti-FTL) increased significantly in hepatocellular carcinoma (HCC). The aim of this study is to verify circulating anti-FTL as a biomarker for the early detection of HCC. PATIENTS AND METHODS: A total of 1565 participants were enrolled and assigned to two independent validation cohorts, including 393 HCC patients, 379 liver cirrhosis (LC) patients, 400 chronic hepatitis (CH) patients, and 393 healthy subjects. The concentration of serum anti-FTL was measured by indirect Enzyme-Linked Immunosorbent Assay (ELISA). Kruskal–Wallis test was used to compare anti-FTL concentrations between HCC group and three control groups. Percentile 95 of anti-FTL absorbance value of healthy group was selected as the cut-off value to calculate the positive rate in each group. The area under receiver operating characteristic curve (AUC) was used to quantitatively describe its diagnostic value. RESULTS: The median concentration of anti-FTL in HCC patients was higher than that in CH patients and healthy subjects, but there was no difference between HCC patients and LC patients. Further analysis showed that there was no difference between early stage LC, advanced stage LC, Child-Pugh A HCC, Child-Pugh B HCC and Child-Pugh C HCC. The positive rate of anti-FTL was 12.2% (48/393) in HCC, 13.5% (51/379) in LC, 6.3% (25/400) in CH and 5.1% (20/393) in healthy subjects, respectively. The AUC of anti-FTL to distinguish LC from CH or healthy subjects were 0.654 (95% CI: 0.615–0.692) and 0.642 (95% CI: 0.602–0.681), respectively. CONCLUSION: Anti-FTL is not a biomarker for the early diagnosis of HCC due to specificity deficiency, but may be helpful for the early detection of LC. |
format | Online Article Text |
id | pubmed-8976487 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-89764872022-04-03 Autoantibody Against Ferritin Light Chain is a Serum Biomarker for the Detection of Liver Cirrhosis but Not Liver Cancer Ren, Pengfei Wang, Keyan Ma, Jie Cao, Xiaoqin Zhao, Jiuzhou Zhao, Chengzhi Guo, Yongjun Ye, Hua J Hepatocell Carcinoma Original Research PURPOSE: Ferritin is a protein that plays an important role in iron metabolism, it consists of two subunits: heavy chain (FTH) and light chain (FTL). Elevated expression of FTL is observed in multiple malignancies. Recent studies have found that the frequency of circulating autoantibody against FTL (anti-FTL) increased significantly in hepatocellular carcinoma (HCC). The aim of this study is to verify circulating anti-FTL as a biomarker for the early detection of HCC. PATIENTS AND METHODS: A total of 1565 participants were enrolled and assigned to two independent validation cohorts, including 393 HCC patients, 379 liver cirrhosis (LC) patients, 400 chronic hepatitis (CH) patients, and 393 healthy subjects. The concentration of serum anti-FTL was measured by indirect Enzyme-Linked Immunosorbent Assay (ELISA). Kruskal–Wallis test was used to compare anti-FTL concentrations between HCC group and three control groups. Percentile 95 of anti-FTL absorbance value of healthy group was selected as the cut-off value to calculate the positive rate in each group. The area under receiver operating characteristic curve (AUC) was used to quantitatively describe its diagnostic value. RESULTS: The median concentration of anti-FTL in HCC patients was higher than that in CH patients and healthy subjects, but there was no difference between HCC patients and LC patients. Further analysis showed that there was no difference between early stage LC, advanced stage LC, Child-Pugh A HCC, Child-Pugh B HCC and Child-Pugh C HCC. The positive rate of anti-FTL was 12.2% (48/393) in HCC, 13.5% (51/379) in LC, 6.3% (25/400) in CH and 5.1% (20/393) in healthy subjects, respectively. The AUC of anti-FTL to distinguish LC from CH or healthy subjects were 0.654 (95% CI: 0.615–0.692) and 0.642 (95% CI: 0.602–0.681), respectively. CONCLUSION: Anti-FTL is not a biomarker for the early diagnosis of HCC due to specificity deficiency, but may be helpful for the early detection of LC. Dove 2022-03-29 /pmc/articles/PMC8976487/ /pubmed/35378780 http://dx.doi.org/10.2147/JHC.S352057 Text en © 2022 Ren et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Ren, Pengfei Wang, Keyan Ma, Jie Cao, Xiaoqin Zhao, Jiuzhou Zhao, Chengzhi Guo, Yongjun Ye, Hua Autoantibody Against Ferritin Light Chain is a Serum Biomarker for the Detection of Liver Cirrhosis but Not Liver Cancer |
title | Autoantibody Against Ferritin Light Chain is a Serum Biomarker for the Detection of Liver Cirrhosis but Not Liver Cancer |
title_full | Autoantibody Against Ferritin Light Chain is a Serum Biomarker for the Detection of Liver Cirrhosis but Not Liver Cancer |
title_fullStr | Autoantibody Against Ferritin Light Chain is a Serum Biomarker for the Detection of Liver Cirrhosis but Not Liver Cancer |
title_full_unstemmed | Autoantibody Against Ferritin Light Chain is a Serum Biomarker for the Detection of Liver Cirrhosis but Not Liver Cancer |
title_short | Autoantibody Against Ferritin Light Chain is a Serum Biomarker for the Detection of Liver Cirrhosis but Not Liver Cancer |
title_sort | autoantibody against ferritin light chain is a serum biomarker for the detection of liver cirrhosis but not liver cancer |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8976487/ https://www.ncbi.nlm.nih.gov/pubmed/35378780 http://dx.doi.org/10.2147/JHC.S352057 |
work_keys_str_mv | AT renpengfei autoantibodyagainstferritinlightchainisaserumbiomarkerforthedetectionoflivercirrhosisbutnotlivercancer AT wangkeyan autoantibodyagainstferritinlightchainisaserumbiomarkerforthedetectionoflivercirrhosisbutnotlivercancer AT majie autoantibodyagainstferritinlightchainisaserumbiomarkerforthedetectionoflivercirrhosisbutnotlivercancer AT caoxiaoqin autoantibodyagainstferritinlightchainisaserumbiomarkerforthedetectionoflivercirrhosisbutnotlivercancer AT zhaojiuzhou autoantibodyagainstferritinlightchainisaserumbiomarkerforthedetectionoflivercirrhosisbutnotlivercancer AT zhaochengzhi autoantibodyagainstferritinlightchainisaserumbiomarkerforthedetectionoflivercirrhosisbutnotlivercancer AT guoyongjun autoantibodyagainstferritinlightchainisaserumbiomarkerforthedetectionoflivercirrhosisbutnotlivercancer AT yehua autoantibodyagainstferritinlightchainisaserumbiomarkerforthedetectionoflivercirrhosisbutnotlivercancer |